Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2019
This article has no abstract
Epistemonikos ID: 81e429766d9fd362a12e64e7a44d65c99dd13318
First added on: Apr 29, 2026